Organogenesis Holdings (ORGO) Share-based Compensation (2018 - 2026)

Organogenesis Holdings' Share-based Compensation history runs 9 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 102.45% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 87.21% decrease from a year earlier, with the FY2025 full-year figure at $1.9 million, down 71.06% from the prior year.
• Share-based Compensation improved to $3.6 million in Q1 2026 per ORGO's latest filing, from -$7.1 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $13.5 million in Q2 2025 and bottomed at -$7.1 million in Q4 2025.
• The 5-year median for Share-based Compensation is $1.9 million (2023), against an average of $2.1 million.
• Across the five-year window, Share-based Compensation surged 1019.3% in 2023 and tumbled 280.11% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $702000.0 in 2022, then gained by 4.13% to $731000.0 in 2023, then surged by 438.44% to $3.9 million in 2024, then tumbled by 280.11% to -$7.1 million in 2025, then soared by 151.29% to $3.6 million in 2026.
• Per Business Quant, the three latest ORGO Share-based Compensation figures stand at $3.6 million (Q1 2026), -$7.1 million (Q4 2025), and $3.1 million (Q3 2025).